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Duchenne muscular dystrophy (DMD) is a devastating progres-
sive disease of striated muscle deterioration that results from the 
loss of the protein dystrophin (1, 2). Most patients with DMD 
develop clinically significant cardiomyopathy during the second 
decade of life, with heart failure emerging as a leading cause of 
death in DMD (3–5). Currently there are no effective therapies for 
the cardiomyopathy of DMD. Numerous therapeutic strategies 
have been proposed to impact striated muscle disease progres-
sion in DMD (6–12). Most of these approaches focus primarily 
on the skeletal muscle manifestations of the disease, often leaving 
the deteriorating heart untreated (6, 7, 9–11). Thus, there is an 
urgent need to pursue new strategies to prevent, halt, or reverse 
the emerging heart disease in DMD.
The availability of small and large animal models of DMD 
has been instrumental in gaining insights into the molecular 
mechanisms of striated muscle disease progression. The golden 
retriever muscular dystrophy (GRMD) animal model of DMD 
has been invaluable for testing leading muscular dystrophy treat-
ment modalities (9, 10, 13–22). Muscular dystrophy in GRMD 
animals closely recapitulates the timing and severity of disease 
progression observed in DMD human patients (23–26). GRMD 
arose from a spontaneous mutation in intron 6 of the dystrophin 
locus that eliminates a splice acceptor site, resulting in the skip-
ping of exon 7 and a subsequent frameshift and premature trun-
cation of the dystrophin protein (27). In addition to the severe 
skeletal muscle pathology, GRMD animals have prominent car-
diac lesions present as early as 6 months of age (25), with ECG 
abnormalities present at 1 year (28) and profound myocardial 
contractile abnormalities by 20 months (29).
In comparison to the muscle pathology present in dystrophic 
humans and dogs, the dystrophic mouse is comparatively mildly 
affected. Nonetheless, the mdx mouse model of DMD has been 
widely used and has been absolutely essential for drug, cell, and 
gene-based therapy investigations. In fact, an understanding of the 
mechanism(s) underlying the more mild disease in the mouse has 
provided unique insights into therapeutic approaches to attenu-
ating the disease progression in larger mammals and human 
patients with DMD. In the dystrophin-deficient mouse heart, the 
primary defect reported at the level of isolated cardiac myocyte is 
a reduced compliance to passive extension (30). Reduced myocyte 
compliance was found to be secondary to calcium influx through 
apparent micro-tears in the cardiac membrane during passive cell 
distension (30). The poor passive compliance of cardiac myocytes 
is physiologically relevant in that during passive filling of the ven-
tricle, individual myocytes are passively extended. The magnitude 
of these passive extensions is greater with the heightened venous 
return during periods of stress (30).
Chemical-based membrane sealants have been tested acutely in 
mdx mice and recently proposed as a new therapeutic approach 
for cardiac membrane stabilization in muscular dystrophy (30). 
This treatment modality aims to directly seal the membrane tears 
that occur in the absence of dystrophin. We recently showed that 
application of the membrane sealant poloxamer 188 (P188) con-
fers acute cardiac protection in the mdx mouse model of DMD 
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(30). However, the translation from single-dose acute studies in 
mdx mice to long-term studies utilizing clinically relevant large 
animal models of DMD is an important and highly challenging 
endeavor. Therefore, a primary aim of the present work was to 
ascertain whether chronic intravascular infusion of membrane-
stabilizing poloxamer would have long-term beneficial effects on 
the marked cardiomyopathy evident in GRMD animals. A second 
aim was to investigate at a cellular level a basis for the more severe 
heart disease in GRMD compared with mdx animals.
We report that chronic infusion of membrane-sealing poloxamer 
to dystrophic dogs reduces myocardial fibrosis, blocks increased 
serum cTnI and brain natriuretic peptide (BNP), and fully prevents 
LV remodeling. To our knowledge, this is the first treatment modal-
ity of any kind demonstrated to be safe and effective at blocking 
advanced heart disease in the GRMD model of DMD. In addition, 
using a novel micro-carbon fiber mechanical assay on living single 
myocytes (30), we report a markedly greater primary cell defect of 
reduced compliance in dystrophic canine myocytes compared with 
mdx mouse myocytes. Interestingly, we find that the GRMD myo-
cardium does not display the compensatory increase in expression 
of the dystrophin homolog utrophin as shown in the mdx heart, a 
finding that could underlie the more severe cell- and organ-level 
pathology in GRMD animals. The implications of these findings 
and their potential translation to human studies are discussed.
Results
GRMD: single-cardiac myocyte studies. Cardiomyopathy in the mdx 
mouse is relatively mild compared with that in either human DMD 
patients or GRMD dogs, suggesting that there may be significant 
differences in the pathophysiology of the disease between these 
species. In the mdx mouse, a reduction in the passive compliance of 
myocytes is an important feature of the disease (Figure 1; ref. 30). 
To determine the passive properties of GRMD myocytes, we iso-
lated membrane-intact cardiac myocytes and subjected them to 
passive extension-tension studies using a unique micro-carbon 
fiber assay (30). Cardiac myocytes isolated from wild-type dogs 
well tolerated passive extensions throughout the physiological 
range of sarcomere lengths (1.8–2.2 μm; ref. 31). In marked con-
trast to wild-type myocytes, GRMD myocytes were highly sensitive 
to passive extension and showed blunted compliance (Figure 1, 
A–C). These effects in GRMD myocytes were more pronounced 
than in the mdx myocyte (Figure 1B; ref. 30). The marked sensi-
tivity to passive extension could result from perturbations of the 
sarcomeric myofilaments. To directly assess this possibility, we 
chemically removed the surface membrane. This solubilization of 
the membrane allows direct investigation of the properties of the 
underlying myofilament-based tension-extension properties of 
the cell. Examination of GRMD dystrophic myofilaments revealed 
passive properties and calcium sensitivity similar to those of wild-
type canine myocytes (Figure 1, D and E). These data indicate that 
the poor compliance of dystrophic myocytes stems from abnor-
malities requiring an intact sarcolemmal membrane.
Baseline in vivo hemodynamics in GRMD animals. In order to 
address the importance of poor myocyte compliance on global 
hemodynamic function of the heart, we subjected GRMD dogs 
to invasive catheter-based hemodynamic assessment. Eight adult 
GRMD dogs and 10 wild-type dogs were utilized in these studies 
(Table 1). Animals were anesthetized, and baseline blood samples 
were drawn. Serum levels of cardiac troponin I (cTnI) were sig-
nificantly elevated in GRMD dogs immediately after induction 
of anesthesia compared with unaffected anesthetized wild-type 
dogs (Figure 2A). At rest, GRMD animals had normal serum cTnI 
levels (see below), indicating that general anesthesia alone pro-
vokes significant cardiac damage in GRMD but not in normal 
dogs. Anesthesia had no significant effect on elevated serum levels 
of creatine kinase (CK) (Figure 2B and below). In contrast to the 
mdx mouse model of DMD (30), dystrophic dog hearts had no 
significant reduction in end-diastolic volume (Figure 3), nor was 
end-diastolic pressure elevated (Table 2).
GRMD dogs had significant hypertension, with increased ven-
tricular and femoral artery systolic pressures, compared with wild-
type dogs (Table 2). Arterial elastance and total peripheral resis-
tance were increased (Table 2), suggesting differences within the 
Figure 1
Mechanical properties of adult cardiac myocytes isolated from GRMD 
dogs. Membrane-intact adult cardiac myocytes were isolated by enzy-
matic digestion from the hearts of 2 untreated 1-year-old GRMD dogs. 
(A) Microcarbon fibers were attached to the isolated myocytes, allow-
ing mechanical manipulations and tension measurements (photo). 
Passive tension tracings from membrane-intact cardiac myocytes 
extended to sarcomere lengths indicated below the tracing. mN, mil-
linewton. (B) Summary passive extension-tension curves are shown 
for membrane-intact cardiac myocytes isolated from wild-type and 
GRMD dogs and mdx mice. (C) Summary of the maximal sarcomere 
length tolerated by the myocytes. *P < 0.05. (D) Solubilization of mem-
branes by detergents permits direct assessment of myofilaments. In a 
solution of nominal calcium, passive extension of myofilaments from 
wild-type and GRMD myocytes revealed no differences (7–8 cells from 
2 dogs for each genotype). (E) Assessment of myofilament calcium 
sensitivity in membrane-solubilized myocytes revealed no differences 
between GRMD and wild-type myocytes. Data are from 5–7 myocytes 
isolated from 2–3 animals. pCa, –log[Ca2+].
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systemic vasculature of the dystrophic dogs. Differences in arteri-
al function may also explain the increase in maximal rate of relax-
ation (dP/dtmin) in the absence of other indicators of improved 
diastolic function (tau and 90% relaxation time; Table 2). 
Early relaxation of ventricular pressure is aided by the filling of 
the coronary vasculature, and poor arterial compliance increas-
es the reflection of the systolic pressure pulse back toward the 
heart. This increase in the reflected pressure pulse increases the 
pressure in the coronary vasculature and in turn increases the 
rate of early ventricular relaxation (32).
After baseline measurements, dobutamine was infused (15 μg/kg/ 
min) until a peak effect was observed, at which time dobutamine 
infusion was stopped. In response to dobutamine, dystrophic 
dogs showed evidence of significant cardiac reserve function, 
with increased systolic and diastolic parameters similar to those 
observed in wild-type dogs (Figure 3 and Table 2). After dobu-
tamine infusion, a dynamic change in ventricular volume was 
observed in wild-type dogs; however, these changes were signifi-
cantly attenuated in dystrophic dogs (Figure 3, E and F).
Acute infusion of membrane sealants in GRMD animals. Dur-
ing the initial hemodynamic protocol, an acute dose of P188 
(460 mg/kg) was administered i.v. over a period of 15 minutes in 
a total volume of 3 ml/kg. This dose was sufficient to normalize 
the end-diastolic volume of the mdx mouse (30). In the GRMD 
heart, this dose of P188 had no significant acute effect on the 
end-diastolic volume (Figure 4A). No significant changes in end-
diastolic volume were observed in wild-type animals infused with 
equivalent doses of P188. Histological examination of heart sec-
tions from 1-year-old GRMD dogs not involved in the chronic 
study revealed the presence of extensive fibrosis when stained 
with Sirius red. This fibrosis takes 2 forms: large lesions associ-
ated with diseased myocardium and increased levels of fibrosis 
surrounding relatively normal myocardium (Figure 4B). Analy-
sis of wild-type sections revealed only small amounts of collagen 
between layers of myocardium (Figure 4C).
We addressed the potential acute effects of P188 on the vas-
culature by determining several measures of vascular function. 
The elastic property of the large arteries was not altered by the 
acute administration of P188 (Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI41329DS1). Similarly, total peripheral resistance and periph-
eral blood pressure were unaffected by P188 (Supplemental Figure 
1). These data are consistent with the selective action of P188 on 
the membranes of dystrophic cardiac myocytes.
During the hemodynamic assay, arrhythmic events were infrequent 
and not different between wild-type and GRMD dogs. Dystrophic 
dogs had significantly increased baseline heart rate and shortened 
P-R interval compared with wild-type dogs, neither of which were 
different after administration of dobutamine (Table 2). The ratio of 
Q-wave to R-wave amplitude was significantly elevated in dystrophic 
dogs, but this effect was not altered by acute dobutamine (Table 2). 
Acute infusion of P188 had no significant effects on ECG measure-
ments in wild-type or dystrophic dogs (Supplemental Figure 2).
Chronic infusion of poloxamer in GRMD animals. Continuous intra-
vascular infusion of P188 or saline vehicle control was initiated 
in adult GRMD animals. Animals were randomized to treatment 
group. Baseline hemodynamic function was similar in the groups 
prior to chronic infusion of P188 or saline (Table 1). After the ini-
tial hemodynamic assessment, a vascular access port was implant-
ed on the flank and connected to an indwelling jugular catheter. 
The carotid artery was repaired, all incisions were closed, and the 
animal was allowed to recover from anesthesia. The next day, an 
infusion of 0.9% saline (0.4 ml/kg/h) was initiated in both groups, 
lasting 1 week. The serum half-life of P188 is 18 hours in dogs (33); 
thus, 1 week is sufficient to wash out any P188 remaining from the 
acute administration. After this washout and a surgery recovery 
period, the saline group continued receiving 0.9% NaCl at a rate 
of 0.4 ml/kg/h, and the P188 treatment group began receiving 
60 mg/kg/h P188 in 0.9% NaCl at the same rate (0.4 ml/kg/h) for 
8 weeks total treatment (Figure 5A).
Table 1
Initial ages, weights, selected baseline hemodynamic parameters, and randomized treatment groups in GRMD and wild-type dogs
Animal no. Genotype Age (mo) Weight (kg) Treatment group LV end-diastolic  LV systolic  
     vol (ml) pressure (mmHg)
1 GRMD 12.0 12.5 Saline 18.7 94.7
2 GRMD 17.0 13.4 Saline 56.7 114.6
3 GRMD 13.8 11.2 P188 23.7 88.5
4 GRMD 17.3 13.2 P188 46.0 130.4
5 GRMD 16.2 14.2 P188 29.9 123.8
6 GRMD 17.9 17.1 Saline 28.7 121.1
7 GRMD 13.2 13.1 P188 24.9 114.3
8 GRMD 13.8 12.7 Saline N/A 95.7
9 WT ≈12 18.7 N/A 52.2 84.1
10 WT ≈12 17.3 N/A 46.0 88.6
11 WT ≈12 18.4 N/A 37.8 90.8
12 WT ≈12 17.7 N/A 39.2 90.4
13 WT ≈12 19.9 N/A 29.0 87.6
14 WT ≈12 19.5 N/A 36.1 98.2
15 WT ≈12 17.9 N/A 46.0 87.6
16 WT ≈12 18.9 N/A 34.1 85.5
17 WT ≈12 17.6 N/A 38.8 77.4
18 WT ≈12 19.4 N/A 50.9 78.9
Ages of wild-type dogs are approximate. N/A, not applicable.
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During the 8-week chronic infusion period, blood samples were 
taken periodically to monitor cardiac injury biomarkers. Saline-
treated GRMD animals had significantly elevated serum concen-
trations of cTnI, evidence of cardiac injury. In contrast, serum cTnI 
levels were completely normal in the P188-treated GRMD animals 
(Figure 5B; P < 0.05 vs. saline). Serum CK levels were unchanged by 
P188 infusion (Figure 5C). The safety of P188 for both the renal and 
hepatic systems was assessed. Figure 5, D and E, shows that during 
the course of the 8-week infusion, the dogs receiving P188 had no 
change in liver enzymes or evidence of azotemia. These results indi-
cate that administration of P188 at 60 mg/kg/h for 8 weeks does 
not result in kidney or liver damage in GRMD animals.
Myocardial fibrosis is a consistent finding in both DMD patients 
and GRMD dogs (Figure 4 and refs. 5, 25, 34, 35). Fibrotic lesions 
are thought to result from myocyte necrosis and subsequent 
inflammatory response. These fibrotic lesions likely increase the 
mechanical strain on neighboring myocytes, causing further myo-
cyte necrosis and subsequent fibrosis over time. To assess the abil-
ity of chronically administered P188 to limit fibrosis, we stained 
cardiac tissue with Sirius red to identify mature fibrotic lesions. 
Upon quantification of the fibrotic area, GRMD animals receiv-
ing P188 had significantly less (P < 0.05) fibrosis than the GRMD 
group receiving saline (Figure 6, A and B). While P188 blunted 
lesion formation in GRMD animals, it did not restore myocar-
dial lesion content to wild-type levels (Figure 6B). Chronic P188 
administration to adult GRMD animals did fully block increases 
in the heart failure biomarker BNP (Figure 6C; P < 0.05).
Prior to randomization for the chronic study, there was no sig-
nificant difference in LV geometry among GRMD saline- versus 
P188-treated animals (Table 1 and Figure 7, A and C). After the 
8-week infusion period, a second hemodynamic protocol was per-
formed on the dystrophic dogs. During the course of the 8-week 
infusion period, GRMD dogs receiving saline developed signifi-
cant LV dilation (P < 0.05; Figure 7). Dramatically, GRMD animals 
receiving P188 had no alteration in LV geometry, with no progres-
sion toward a dilated cardiac phenotype. LV geometry differences 
between saline and P188-treated GRMD animals were evident 
throughout the hemodynamic testing protocol (Figure 7C) and 
were particularly pronounced after the administration of dobuta-
mine (Figure 7, C–F). The dilation of ventricular geometry in the 
saline GRMD group is consistent with ongoing cardiac injury and 
necrosis/fibrosis. Hemodynamic data also showed a significant 
enhancement in the isovolumic relaxation function in P188-treated 
GRMD compared with saline-treated GRMD animals (Figure 7D). 
The mechanism by which chronic P188 mediates improvements in 
diastolic function is not clear, but its determination would likely 
be of further benefit in DMD patients, where diastolic dysfunction 
is an early marker of cardiac disease (36).
Myocytes isolated from dystrophic dogs after infusion with P188 
or saline showed some significant differences in calcium handling. 
The amplitude of calcium release and kinetics of relaxation were both 
improved in myocytes isolated from GRMD dogs receiving chronic 
P188 infusion (Supplemental Figure 3). These improvements in cal-
cium handling resulted from the improved myocyte health in the 
group treated with P188, as opposed to a direct action of P188, which 
is washed out during the myocyte isolation procedure.
To determine the effects of chronic P188 administration on the 
primary cellular defect of dystrophin-deficient cardiac myocytes, we 
examined the passive tension-extension properties of isolated myo-
cytes at the end of the infusion protocol (Figure 8A). As seen with 
myocytes from untreated GRMD dogs (Figure 1), single myocytes 
isolated from GRMD animals receiving saline were highly sensitive to 
even small extensions in length. In addition to showing poor myocyte 
compliance, saline-infused GRMD myocytes were highly susceptible 
to terminal contracture after mild sarcomeric extension (Figure 8, 
A and C). Myocytes isolated from GRMD dogs receiving chronic 
P188, but with P188 washed out during the isolation procedure, had 
Figure 2
Elevations in serum cTnI after induction of anesthesia in GRMD animals. 
Serum samples collected within minutes of induction of general anes-
thesia reveal significant elevations in a biomarker of cardiac injury (A). 
(B) Significant elevations in serum CK in GRMD dogs. Values are 
shown as mean ± SEM; n = 8–10. ‡P < 0.05 by t test.
Figure 3
Baseline hemodynamic function in GRMD animals. (A and B) Rep-
resentative LV pressure tracings during inferior vena cava occlusion 
in wild-type (A) and GRMD (B) hearts. (C and D) Summary of end-
diastolic volume (C) and stroke volume (D) at rest (black bars) and 
in response to dobutamine (white bars). Summaries of the change 
in mean end-diastolic volume (EDV) (E) and end-systolic volume 
(ESV) (F) observed in response to dobutamine. Values are shown as 
mean ± SEM. *P < 0.05 versus wild-type.
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passive extension properties similar to those of dystrophic myocytes 
from untreated animals (Figure 8A), demonstrating that the P188 
activity is readily reversed. However, acute administration of P188 to 
isolated GRMD myocytes, regardless of previous treatment, corrected 
the passive tension-extension relationship to levels similar to those of 
dystrophin-replete canine myocytes (Figure 8, B and C). These data 
demonstrate that the severely attenuated passive extension-tension 
relationship of GRMD myocytes occurs secondary to the formation 
of membrane tears that are corrected in the presence of P188.
Utrophin expression in GRMD myocardium. The mechanism under-
lying blunted cellular compliance of GRMD cardiac myocytes is 
unknown. The mdx heart shows a marked upregulation of the dys-
trophin homolog utrophin, which may explain a mechanism by 
which mdx mice are relatively spared from the severe pathology 
observed in dystrophin-deficient dogs or humans (37, 38). To deter-
mine whether similar upregulation occurs in GRMD hearts, we 
assessed utrophin levels in crude microsomal membranes isolated 
from the hearts of 2 untreated GRMD and 3 wild-type dogs. These 
studies revealed that, in contrast to the mdx mouse, the GRMD 
dogs lack upregulation of utrophin in their hearts (Figure 9). 
Furthermore, the expression of utrophin was unaltered by the 
chronic infusion of P188 (Supplemental Figure 4).
Discussion
This study provides the first evidence to our knowledge of an effec-
tive long-term treatment for the pronounced cardiomyopathy in 
a large animal model of DMD. Chronic intravascular infusion of 
membrane-sealing tri-block copolymer P188 was found to be safe 
and highly effective at limiting myocardial fibrosis and preventing 
the emergence of LV dilation in GRMD dogs, a severely affected 
animal model of DMD. Because the natural history of muscular 
dystrophy in canines and humans is comparable, both in sever-
ity and timing, and as poloxamers are used in human patients 
for other indications (39–42), these findings raise the potential 
of translating this approach as a viable treatment modality for 
human DMD patients.
Mechanism of cardiac disease severity in GRMD animals. The only pub-
lished studies on membrane sealants and the cardiomyopathy of 
DMD have centered on single-dose acute applications of poloxam-
er in the mdx mouse (30). The mdx mouse model of DMD contin-
ues to be valuable in elucidating mechanisms of disease and for the 
testing of new experimental therapeutics. One challenge for these 
investigations, however, is the somewhat mild cardiomyopathy in 
the mdx mouse compared with the severely affected GRMD ani-
mals. In addition, intracellular Ca2+ handling in the mouse heart 
Table 2
Summary of pretreatment hemodynamic and electrocardiographic parameters at baseline and during acute dobutamine infusion
 GRMD Baseline GRMD dobutamine WT baseline WT dobutamine
Weight (kg) 13.43 ± 0.61A 13.43 ± 0.61A 18.53 ± 0.28 18.53 ± 0.28
Systolic function
LV systolic pressure (mmHg) 110.4 ± 5. 5A 131.7 ± 3.9 86.91 ± 1.9 127.6 ± 4.4
dP/dtmax (mmHg/s) 2,154 ± 172 5,756 ± 512 1,789 ± 82 6,120 ± 528
Contractile index (/s) 40.7 ± 5.3 77.8 ± 6.0 36.9 ± 2.0 79.5 ± 4.3
LV end-systolic vol (ml) 23.9 ± 4.8 17.8 ± 4.6 29.4 ± 3.4 15.2 ± 2.5
Stroke volume (ml) 8.7 ± 1.1A 11.1 ± 1.5 13.6 ± 0.8 15.9 ± 2.1
Ejection fraction (%) 28.8 ± 4.2 42.0 ± 4.9 33.4 ± 3.5 52.4 ± 6.3
Stroke work (mmHg · ml) 748.8 ± 103.9 1,215 ± 205.6 931.1 ± 82.2 1506 ± 242.3
Cardiac output (ml/min) 892.9 ± 118.3 1,089 ± 142.5 1,167 ± 84.4 1645 ± 277.8
Cardiac index (ml/min/kg) 68.4 ± 10.3 84.2 ± 14.0 62.8 ± 4.1 89.5 ± 15.9
ESPVR, slope 4.45 ± 0.46A 6.51 ± 0.83A 2.29 ± 0.28 2.89 ± 0.57
ESPVR, intercept 0.50 ± 5.17 –1.79 ± 3.54 -6.91 ± 5.80 –5.98 ± 8.80
PRSW, slope 45.66 ± 5.88 71.62 ± 7.30 35.63 ± 3.49 66.21 ± 9.55
PRSW, intercept 16.01 ± 5.56 9.67 ± 3.90 17.51 ± 4.59 4.55 ± 5.72
Diastolic function
LV end-diastolic vol (ml) 32.7 ± 5.1 28.9 ± 5.3 43.1 ± 3.1 31.1 ± 2.2
LV end-diastolic pressure (mmHg) 7.05 ± 0.38 8.20 ± 0.64 7.03 ± 0.82 10.5 ± 1.4
dP/dtmin (mmHg/s) 3,339 ± 314A 4,862 ± 329A 2,324 ± 141 3,654 ± 245
RT-90 (ms) 46.3 ± 7.1 37.4 ± 6.4 48.8 ± 2.4 42.0 ± 1.6
LVP tau (ms) 27.6 ± 1.1 18.9 ± 1.1 26.6 ± 1.0 18.1 ± 1.7
Electrocardiograph
Heart rate (bpm) 104.9 ± 5.4A 100.1 ± 6.5 86.0 ± 4.7 105.1 ± 11.7
P-R interval 94.1 ± 3.8A 89.4 ± 9.9 124.2 ± 8.0 94.8 ± 3.4
Q/R ratio (lead II) 0.435 ± 0.021A 0.433 ± 0.029A 0.236 ± 0.033 0.224 ± 0.037
Arterial function
Systemic arterial BP, systolic (mmHg) 136.9 ± 8.6A 179.2 ± 8.2A 105.2 ± 3.7 137.8 ± 7.0
Systemic arterial BP, diastolic (mmHg) 74.8 ± 5.3A 78.0 ± 3.2A 59.6 ± 2.9 61.0 ± 2.8
Arterial elastance (mmHg/ml) 16.0 ± 2.5A 14.2 ± 2.1A 6.3 ± 2.3 6.3 ± 1.6
Total peripheral resistance (mmHg · min/ml) 0.109 ± 0.019A 0.132 ± 0.025A 0.058 ± 0.018 0.064 ± 0.021
Values are shown as mean ± SEM (n = 7–10). AP < 0.05 versus wild-type. ESPVR, end-systolic pressure-volume relationship; PRSW, preload recruitable 
stroke work; RT-90, relaxation time to 90% of peak height.
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is markedly different from that in the dog heart, which is highly 
comparable to human myocardium (43). This is an important con-
sideration, as the primary defect in the cardiac myocytes of mdx 
mice is micro-tears in the sarcolemma during passive cell disten-
sion leading to transient Ca2+ entry. This leads to heightened pas-
sive tension-extension properties of the mdx myocyte (30). Because 
GRMD animals are known to have pronounced cardiomyopathy 
(25, 28, 29, 44), it was important to ascertain passive tension-
extension function of the membrane-intact GRMD myocyte for 
comparison with that obtained recently in the mdx myocyte (30). 
Results here showed significantly reduced compliance of GRMD 
compared with mdx myocytes (Figure 1) (30). Even for small excur-
sions in length from baseline sarcomere lengths (>1.8 μm), GRMD 
myocytes had abnormally high passive tension not seen previously 
in mdx or wild-type cardiac myocytes. The quantitative difference 
in compliance defects between dystrophic dog and mouse isolated 
myocytes suggests important mechanistic differences in cell struc-
ture/function in these models. Another important new finding of 
this study is that membrane-intact cardiac myocytes from GRMD 
dogs lack a key cellular adaptation present in the mdx myocardi-
um in terms of upregulation of the dystrophin homolog utrophin 
(37, 38). Utrophin is highly homologous to dystrophin, sharing 
many of the same structural domains (45). In wild-type mice, very 
little utrophin is expressed in the heart. In the mdx mouse, where 
dystrophin is absent, utrophin protein expression is significantly 
increased and localized to the sarcolemma, where dystrophin is 
normally found (37, 38). Furthermore, transgenic expression of 
utrophin in dystrophin-deficient muscle prevents pathology and 
restores normal function (46, 47). Utrophin is thought to function 
as a dystrophin surrogate, providing increased structural integrity 
to the dystrophin-deficient membrane, reducing the prevalence 
of membrane tears, and limiting myocytes loss. In this context, 
our new finding that utrophin expression is not increased in the 
GRMD myocardium provides a mechanism to account for the 
increased mechanical stiffness and susceptibility to damage of the 
GRMD compared with mdx myocardium.
These dystrophic myocyte structure-function results form the 
core of a model to help explain the marked organ-level disease 
severity in GRMD animals (Figure 10). Findings here and elsewhere 
(28, 30) show that myocyte passive distension, as would normally 
occur during diastolic filling of the ventricle, are shifted markedly 
leftward in dystrophin deficiency (Figure 10A), indicating marked 
Figure 4
Preexisting fibrotic lesions and ventricular volume in GRMD dogs. (A) 
Assessment of end-diastolic volume before and after acute infusion 
of P188 in GRMD and wild-type canines. Values are shown as mean 
± SEM. (B) Representative Sirius red–stained histopathological sec-
tions from untreated adult GRMD animals. In brightfield images (left), 
collagen appears red; in polarized light, Sirius red–stained collagen 
exhibits birefringence, allowing it to be visualized as green-yellow light 
(right). Upper images show a large lesion with extensive fibrosis and 
degenerating myocytes. Lower images show strands of collagen that 
extend through areas of relatively normal myocardium (arrows). (C) 
Identical stains of wild-type myocardium. Scale bars: 100 μm.
Figure 5
Summary of disease biomarkers during chronic administration of P188 
in GRMD animals. (A) Outline of study design for the chronic adminis-
tration of P188 (n = 4) or saline (n = 4) in GRMD animals. (B–E) Serum 
chemistry data from samples take biweekly throughout the chronic 
infusion period; shown are (B) cTnI (dashed line indicates wild-type 
canine values), (C) CK, (D) aspartate transferase (AST) and alkaline 
phosphatase (ALP), and (E) blood urea nitrogen (BUN) and creatinine. 
Values are shown as mean ± SEM; 4–8 animals per group. *P < 0.05, 
significant treatment effect by 2-way ANOVA analysis.
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stiffness of the membrane-intact cell. In model systems whereby 
dystrophin deficiency is accompanied by upregulation of utrophin 
(e.g., mdx), myocyte compliance is partially restored toward normal 
(Figure 1B and Figure 10B). Differences in the severity of the cell 
compliance defect could, in turn, account for the greater fibrosis 
in GRMD than mdx hearts owing to increased myocyte loss. The 
results obtained here suggest that lack of upregulation of utro-
phin in GRMD myocytes causes significant membrane destabiliza-
tion, limiting cell membrane integrity and therefore compliance, 
culminating in worsening organ-level pathology (Figure 10B).
Chronic membrane sealant and the dystrophic heart. The presence of 
membrane micro-tears constitutes a primary cellular deficit of 
dystrophin-deficient cardiac myocytes that is readily corrected 
by the direct application of membrane sealants. Membrane seal-
ants prevent breaches in membrane barrier function by inserting 
into the disrupted phospholipid bilayers of membranes (30, 48). 
In this context, it is surprising that P188 had no acute effect on 
in vivo hemodynamics in GRMD animals. This contrasts with 
P188’s immediate acute effects of restoring normal ventricular 
geometry to mdx hearts in vivo (30). We speculate that lack of an 
acute organ-level effect in GRMD animals relates to the greater 
fibrosis present in the adult GRMD heart, such that it provides 
temporary structural support, preventing the acute expansion of 
the ventricle despite the normalization of cardiac myocyte passive 
properties. However, as cell lysis and subsequent fibrotic remod-
eling ensues, GRMD progresses to a dilated cardiomyopathy, as 
reported here (Figure 8B).
What accounts for the beneficial effects of long-term application 
of P188 on GRMD hearts? We propose that long-term administra-
tion of P188 maintains myocardial membrane function and pre-
vents myocardial necrosis, as shown by significantly lower levels 
of cTnI in the treated GRMD dogs. The prevention of myocardial 
necrosis by chronic P188 can also account for the reduction in 
the amount of fibrosis in the P188-treated GRMD heart. Attenu-
ation of the number and size of lesions present in the heart would 
decrease the stress on the remaining viable myocardium and serve 
to limit cardiac remodeling and block ventricular dilation. It is of 
note that the progression of disease appears to accelerate after the 
initiation of the chronic infusion protocol in GRMD dogs receiv-
ing saline alone, as measured by biomarkers of cardiac necrosis. 
The reasons for this observed acceleration are likely to be multi-
factorial, including residual cardiac injury after initial surgical 
procedure, increased manipulation during the infusion proto-
col, and the extra weight of the infusion pump and solutions on 
these animals. However, none of these would be expected to dis-
proportionately affect saline-infused animals. All of these factors 
would increase the stress on viable cardiac myocytes. This extra 
stress would be expected to increase the frequency of mechanically 
induced disruptions of membrane integrity that are an important 
inciting event in the pathophysiology of dystrophin deficiency in 
the heart. This accelerated disease progression makes the protec-
tive effects of P188 even more notable. Under conditions in which 
untreated dystrophic hearts are deteriorating, P188 appears to halt 
the progression of the disease.
The loss of membrane integrity results from mechanical sheer 
stresses placed on the membrane by the movements of the 
extracellular matrix and the underlying myofilaments. These 
stresses are more frequent and greater in magnitude during 
times of cardiac stress, suggesting that membrane sealants may 
be particularly effective during these events. One important and 
predictable cardiac stressor is general anesthesia. DMD patients 
commonly undergo major surgical procedures to correct orthope-
dic dysfunction. These procedures have the potential to result in 
significant cardiac stress secondary to blood loss and hypotension. 
Moreover, in untreated GRMD animals, general anesthesia alone 
was sufficient to induce significant increases in cTnI, a marker 
of myocardial necrosis and cardiac injury. Given the low rate of 
cardiac regeneration, the progressive and unabated loss of cardiac 
myocytes would ultimately cause ventricular dilation and defi-
cits in global cardiac function. Thus, cardiac myocyte membrane 
damage is an inciting event that initiates a cascade of deleterious 
processes that eventually lead to cardiomyopathy and ventricular 
Figure 6
Chronic P188 treatment limits myocardial fibrosis and 
blocks elevation in BNP in GRMD animals. (A) Sirius red 
staining of myocardial sections reveals extensive fibro-
sis in GRMD hearts. Collagen appears red in brightfield 
images and yellow-green in polarized images. Scale bars: 
400 μm. (B) Quantification of collagen content from 16–24 
sections from 4 dogs in each group. (C) Serum BNP 
levels taken before (GRMD-Pre) and after the chronic 
infusion protocol. Values are shown as mean ± SEM; 
4–8 animals per group. *P < 0.05 versus wild-type; 
‡P < 0.05 versus GRMD (saline) group. All data were 
analyzed with 1-way ANOVA and a Bonferroni’s multiple 
comparisons post-hoc test.
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remodeling. Our results suggest that application of membrane 
sealants during times of anticipated cardiac stress would disrupt 
this spiral of cardiac damage early on, thus halting the progression 
of the dystrophic heart disease.
In summary, our data establish a cellular basis for the severe 
cardiac damage observed in dystrophin-deficient dogs. The cel-
lular defect of marked reduction in myocyte compliance, due to 
dystrophin deficiency and the absence of utrophin upregulation, 
was corrected by membrane sealant P188. Chronic application 
of P188 was highly effective in preventing cardiac injury and 
ventricular remodeling in a severely affected large animal model 
of DMD. P188 is FDA approved for short-term applications in 
humans. In this chronic study in GRMD animals, P188 was also 
shown to be safe in GRMD animals. These findings have sig-
nificant clinical relevance, as P188 has the potential to halt the 
progression of dystrophic cardiomyopathy, which is the second 
most common cause of death in DMD patients. In addition, we 
further speculate that membrane sealant therapy may extend to 
a myriad of acquired cardiac diseases in which dystrophin struc-
ture-function and membrane integrity are known to be compro-
mised, including viral myocarditis, myocardial ischemia, and 
heart failure (49–52).
Methods
Animals. Adult GRMD dogs were obtained from a colony maintained at 
the University of North Carolina, Chapel Hill. GRMD dogs were identified 
based on elevation of serum CK and subsequently developed characteris-
tic clinical signs. Genotype was confirmed by PCR in most dogs. Approxi-
mately age-matched, heartworm-negative normal dogs of mixed breed 
provided by R & R Research were used as wild-type dogs. All animals were 
used and cared for according to principles outlined in the NIH Guide for the 
care and use of laboratory animals (NIH publication no. 85-23. Revised 1985) 
and protocols reviewed and approved by the Institutional Animal Care and 
Use Committee of the University of Minnesota.
Vascular access port placement and hemodynamics. Premedication consisted of 
morphine (1 mg/kg; i.m.) and midazolam (0.3 mg/kg; i.m.); some of the wild-
type dogs required a supplemental dose of acepromazine (0.05 mg/kg; i.m.). 
Anesthesia was induced with intravenous propofol (4 mg/kg) and main-
tained at a surgical plane of anesthesia with either isoflurane or sevoflu-
rane. After placement of a femoral arterial catheter, the left jugular vein and 
carotid artery were isolated. A 6 French introducer was inserted into the left 
carotid and secured with a purse-string suture. Under fluoroscopic guidance, 
a 5 French 10 electrode pressure-volume catheter (SPR-554-11, Millar Instru-
ments) was advanced through the aortic valve into the lumen of the left ven-
tricle and positioned to give strong signals in all 7 segments and appropriate 
Figure 7
Eight weeks of P188 administration prevents LV remodeling in GRMD 
animals. Catheter-based intraventricular recordings demonstrate signifi-
cant ventricular remodeling in GRMD dogs receiving saline infusion. (A 
and B) Representative tracings of pressure-volume loops from before 
the treatment (A) and after the chronic infusion protocol (B). (C) Monitor-
ing of LV end-diastolic volume during the terminal hemodynamic proto-
col. Offset at the far left are baseline data from the initial hemodynamic 
protocol prior to chronic infusion. *P < 0.05 (see Methods). (D–F) Com-
parisons of hemodynamic data taken during the peak of the dobutamine 
response (≈10 minutes after infusion); LV pressure tau (D), end-diastolic 
volume (E), and end-systolic volume (F). Groups consist of 3–4 dogs. 
‡P < 0.05 by t test. For C–F, values are shown as mean ± SEM.
Figure 8
In vitro passive tension-extension relationships in intact GRMD cardiac 
myocytes after chronic infusion. After the 8-week infusion, myocytes 
were isolated from P188- (red) and saline-infused (blue) GRMD and 
wild-type dogs. Passive tension-extension relationships of dystrophic 
cardiomyocytes in the absence (A) and presence (B) of acute appli-
cation of 150 μM P188 are shown. The black curve in B is derived 
from wild-type myocyte data in A and is included as a reference. SL, 
sarcomere length. (C) Comparisons of maximum stable sarcomere 
length (Max SL) between the groups. *P < 0.05 versus wild-type; 
†P < 0.05 versus chronic saline GRMD group; ‡P < 0.05 versus chronic 
P188 GRMD group. Values are shown as mean ± SEM. All points 
were derived from 5–7 myocytes isolated from 4–5 dogs. All data were 
analyzed with 1-way ANOVA and Bonferroni’s multiple comparisons 
post-hoc test. MD, GRMD.
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pressure-volume loops. The catheter interfaced with a MPVS Ultra signaling 
conditioning unit (Millar Instruments), and data were collected by a DAQ-16 
acquisition unit and Ponemah software package (DSI). During the initial 
hemodynamic protocol, measurements were taken at baseline, after an infu-
sion of dobutamine (15 μg/kg/min), after a return to baseline values, after 
an infusion of P188 (460 mg/kg), and after a second dobutamine infusion. 
Concurrently with the hemodynamic study, a pulmonary artery catheter 
was placed, its position verified by observation of a pulmonary artery pres-
sure tracing. Also implanted was a stainless steel vascular access port (VAP; 
CP4AC-5IS-SS, Access Technologies). The VAP was implanted approximately 
5 cm caudal to the spine of the scapula and approximately 10 cm from the 
dorsal midline. A 22-gauge right-angle Huber needle was introduced into the 
VAP and secured with 2-0 Prolene. A 5 French silicone catheter was tunneled 
subcutaneously to the neck incision. After completion of the hemodynamic 
protocol, a bolus of 10% NaCl was injected directly into the pulmonary circu-
lation, allowing for calibration of the conductance volume. After removal of 
the pulmonary artery catheter, the heparin-flushed catheter connected to the 
VAP was then introduced into the jugular vein such that the tip was near the 
right atrium. At the completion of the hemodynamic protocol, the carotid 
was repaired, all skin incisions were closed, and the animals were allowed to 
recover. Average induction to extubation period was approximately 6 hours. 
Once fully recovered, animals were placed in fitted jackets (Lomir Biomedi-
cal) that protected the VAP site.
Figure 9
Utrophin expression in GRMD hearts. (A) Western blot analysis of 
utrophin and dystrophin KCl-washed crude microsomal membranes 
isolated from wild-type and GRMD dog hearts. (B) Quantification of the 
levels of utrophin expression observed in A.
Figure 10
Model of the cellular basis for severe cardiomyopathy in GRMD animals. (A) A schematic of membane-intact cardiac myocyte passive tension-
extension curves. In the presence of dystrophin, myocytes show compliance throughout the working sarcomere length range (black line). In 
the absence of dystrophin, the cardiac myocytes become very noncompliant and resistant to passive extensions (gray line), as seen in GRMD 
myocytes. Upregulation of utrophin partially restores the passive extension-tension properties of the dystrophin-deficient myocytes (dotted line), 
as seen in the mdx myocytes. (B) Cellular model depicting the normal mechanical stabilizing function of dystrophin (blue) in wild-type animals. In 
wild-type cardiac myocytes, upon passive cell extension (lower scheme), dystrophin protects the membrane from damage. In the mdx myocytes, 
dystrophin is absent, but utrophin (red) is upregulated and partially replaces the mechanical buffering properties of dystrophin. This provides 
some, but not full protection of the membrane from mechanical damage. Hence, with cell extension, there is some membrane damage. In the 
dystrophin-deficient dog myocytes (GRMD), utrophin is not upregulated. Thus, upon cell extension, there is more damage to the membrane.
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Chronic infusion protocol. An ambulatory infusion pump (Ambit, Sorenson 
Medical) was inserted into a jacket pocket, and a 500-ml i.v. bag was placed 
into a second pocket. In total, the jacket, pump, and a full bag of fluid 
weighed slightly more than 1 kg (6%–9% of body weight). Saline infusions 
began the morning after the implantation of the VAP and were continued 
for 7 days, at which time baseline blood samples were taken and dogs in 
the P188 treatment group started receiving P188 infusion. National For-
mulary grade P188 was provided by BASF.
Myocyte isolation. After the terminal hemodynamic study, the animals 
were euthanized by a barbiturate overdose, the chest was rapidly opened 
through a lateral thoracotomy, and the heart was removed and placed into 
ice-cold Krebs solution. Sections of myocardium were cut into 5-mm cubes 
and digested in a solution containing nominal calcium, type 2 collage-
nase (250–300 U/ml; Wothington Biochemical Corp.), and hyaluronidase 
(250–500 U/ml; H3506, Sigma-Aldrich). After an initial period of diges-
tion, the heart sections were gently triturated to further disperse the isolat-
ed cells. Calcium was reintroduced in a stepwise manner; calcium-tolerant 
myocytes were then utilized. Other representative portions of myocardium 
were placed in formalin and embedded in paraffin for sectioning.
Image acquisition and analysis. Images of sectioned tissues were obtained 
on an inverted Axio Observer Z-1 with a motorized stage (Zeiss). Montage 
images were collected and stitched by AxioVision software (Zeiss). Com-
posite images were analyzed by a custom-written edge-detection routine 
using MatLab (R2008a, MathWorks).
Western blotting. KCl-washed crude microsomes were prepared as previously 
described (24, 53). Membrane proteins (20 μg) were separated by SDS-PAGE 
using a 4%–20% gradient (Bio-Rad). Proteins were then transferred to nitro-
cellulose by the procedures of Towbin et al. (54). Transferred proteins were 
detected using 1:1,000 polyclonal anti-dystrophin (Abcam) or monoclonal 
anti-utrophin (MANCHO3; DSHB). The MANCHO3 developed by G.E. 
Morris (55) was obtained from the Developmental Studies Hybridoma Bank 
developed under the auspices of the National Institute of Child Health and 
Human Development and maintained by the University of Iowa Department 
of Biology. Band intensities were quantified by an Odyssey scanner (LiCor), 
and secondary antibodies were goat anti-mouse IgG conjugated to either 
Alexa Fluor 680 (Invitrogen) or IRDye 800 (Rockland Immunochemicals).
Statistics. Statistical analysis was performed using Prism version 5.0 
(GraphPad Sofware), and a custom SAS-PROC MIXED model of covari-
ance accounting for both fixed and random effects was used to perform 
analysis of repeated measures (SAS). Statistical significance was defined as 
P < 0.05. Data are presented as mean ± SEM.
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